biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP patent portfolio — 18 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
MEREO BIOPHARMA GROUP patents
18 pharmaceutical patents indexed for MEREO BIOPHARMA GROUP. 0 expire within 24 months.
MEREO BIOPHARMA GROUP has 18 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12173058
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
granted -
US 11701341
Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
granted -
US 11512128
VEGF/DLL4 binding agents and uses thereof
granted -
US 11434204
Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
granted -
US 11339213
Methods and compositions for treatment of cancer
granted -
US 11234967
Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
granted -
US 11230596
Methods for treatment of cancer comprising TIGIT-binding agents
granted -
US 11136384
Methods for treatment of cancer comprising TIGIT-binding agents
granted -
US 11129810
Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
granted -
US 10995071
Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
granted -
US 10961305
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
granted -
US 10934260
Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
granted -
US 10617674
Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
granted -
US 10603306
Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
granted -
US 10064844
Pharmaceutical compositions comprising an aromatse inhibitors
granted -
US 9750724
Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
granted -
US 9370505
Pharmaceutical compositions comprising an aromatse inhibitors
granted -
US 9339491
Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
granted
Frequently asked questions
How many patents does MEREO BIOPHARMA GROUP have?
18 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do MEREO BIOPHARMA GROUP patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.